A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Maria Fulgenzi CA, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar F, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie J, Pinato DJ

Open source

DOI
10.1016/j.jhep.2026.05.018
Published
2026 Jun 15
Container
Journal of hepatology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jhep.2026.05.018,
  title = {A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.},
  author = {Lombardi P and Ramon-Gil E and Raja RQ and Brunetti L and Manfredi GF and Zhou Z and Merces G and Cappuyns S and Maria Fulgenzi CA and D'Alessio A and Torkpour A and Celsa C and Stefanini B and Yang H and Crowley F and Marron TU and Saeed A and Pinter M and Scheiner B and Huang YH and Lee PC and Nishida N and Po-Ting Lin R and Dalbeni A and Vivaldi C and Masi G and Rohlen N and von Felden J and Kaseb A and Galle PR and Kudo M and Hsu WF and Rimassa L and Parisi A and Kelley RK and Toyoda H and Pirisi M and Jabar F and Rakaee M and Cabibbo G and Cammà C and Piscaglia F and Hwang S and Shin DJ and Li M and Dekervel J and Guerra N and Meyer T and Reeves HL and Bengsch B and Daniele G and Mann DA and Chon HJ and Leslie J and Pinato DJ},
  year = {2026},
  journal = {Journal of hepatology},
  doi = {10.1016/j.jhep.2026.05.018},
  url = {https://doi.org/10.1016/j.jhep.2026.05.018}
}

RIS

TY  - JOUR
TI  - A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
AU  - Lombardi P
AU  - Ramon-Gil E
AU  - Raja RQ
AU  - Brunetti L
AU  - Manfredi GF
AU  - Zhou Z
AU  - Merces G
AU  - Cappuyns S
AU  - Maria Fulgenzi CA
AU  - D'Alessio A
AU  - Torkpour A
AU  - Celsa C
AU  - Stefanini B
AU  - Yang H
AU  - Crowley F
AU  - Marron TU
AU  - Saeed A
AU  - Pinter M
AU  - Scheiner B
AU  - Huang YH
AU  - Lee PC
AU  - Nishida N
AU  - Po-Ting Lin R
AU  - Dalbeni A
AU  - Vivaldi C
AU  - Masi G
AU  - Rohlen N
AU  - von Felden J
AU  - Kaseb A
AU  - Galle PR
AU  - Kudo M
AU  - Hsu WF
AU  - Rimassa L
AU  - Parisi A
AU  - Kelley RK
AU  - Toyoda H
AU  - Pirisi M
AU  - Jabar F
AU  - Rakaee M
AU  - Cabibbo G
AU  - Cammà C
AU  - Piscaglia F
AU  - Hwang S
AU  - Shin DJ
AU  - Li M
AU  - Dekervel J
AU  - Guerra N
AU  - Meyer T
AU  - Reeves HL
AU  - Bengsch B
AU  - Daniele G
AU  - Mann DA
AU  - Chon HJ
AU  - Leslie J
AU  - Pinato DJ
PY  - 2026
JO  - Journal of hepatology
DO  - 10.1016/j.jhep.2026.05.018
UR  - https://doi.org/10.1016/j.jhep.2026.05.018
ER  -

APA

P, L., E, R., RQ, R., L, B., GF, M., Z, Z., G, M., S, C., CA, M. F., A, D., A, T., C, C., B, S., H, Y., F, C., TU, M., A, S., M, P., B, S., YH, H., PC, L., N, N., R, P. L., A, D., C, V., G, M., N, R., J, V. F., A, K., PR, G., M, K., WF, H., L, R., A, P., RK, K., H, T., M, P., F, J., M, R., G, C., C, C., F, P., S, H., DJ, S., M, L., J, D., N, G., T, M., HL, R., B, B., G, D., DA, M., HJ, C., J, L., & DJ, P. (2026). A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.. Journal of hepatology. https://doi.org/10.1016/j.jhep.2026.05.018

Source records